Post hoc analyses of the PREMIER trial data reported that MTX-treated RA patients with low Hb levels were significantly associated with faster radiographic progression/damage over a 2-year study period [9]; also the study suggested that low Hb was a valuable DAS28-CRP-independent indicator of joint damage progression. Here, CRP is linked to rheumatoid arthritis.